Oyagen, Inc.

University of Rochester

Cannametrix, LLC

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Thomas Jefferson University

Harold C Smith

Ryan P Bennett

Joseph E Wedekind

James McGrath

Hui Zhang

Peter B Jahrling

Andrew Brooks

Xia Jin

Ryan Patrick Bennett

The present disclosure relates to, inter alia, cell-based assays, recombinant cell lines, and methods for quantifying the potency and efficacy of cannabinoids and/or terpenoids.

Cell-based assay for quantifying the potency and efficacy of cannabinoids and/or terpenoids, and methods of use thereof

Disclosed herein are methods, formulations, and kits for treating coronavirus infections, including Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infections and SARS-CoV-2 infections. Further disclosed are stop-gap methods for controlling the spread of coronavirus infections and the emergence of drug resistant strains of coronavirus.

Method for treating coronavirus infections

Disclosed herein are methods, formulations, and kits for treating coronavirus infections, including Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infections. Further disclosed are stop-gap methods for controlling the spread of coronavirus infections and the emergence of drug resistant strains of coronavirus.

Disclosed herein are methods for treating an Ebola virus and inhibiting the transmission and propagation thereof.

Methods of treating and inhibiting Ebola virus infection

Disclosed herein are compounds useful for treating and/or preventing HIV infections and the transmission of HIV from an infected subject.

Compounds, compositions, and methods for treating human immunodeficiency virus

The present invention relates to the use of camptothecin derivatives as anti-HIV agents that disrupt self-association of the viral infectivity factor (Vif) found in HIV and other retroviruses. The present invention also relates to methods of identifying agents that disrupt VIf self-association and methods of using these agents, including methods of treating or preventing HIV infection.

Camptothecin derivatives as anti-HIV agents and methods of identifying agents that disrupt Vif self-association

Disclosed are methods and compositions related to the structure and function of APOBEC3G.

Methods and compositions related to the structure and function of APOBEC3G

The present invention provides compositions and methods related to determining the severity of viral infections and identifying antiviral agents. In certain embodiments, the invention comprises determining the expression level of APOBEC-1 related proteins, where the expression level of APOBEC-1 related proteins is an indicator for disease severity and/or effectiveness of a potential antiviral agent. In one embodiment, the present invention provides for a method of screening for an antiviral agent.

Human immunodeficiency virus antiviral screening assay involving the detection of CEM15 expression

The invention provides a porous nanoscale membrane. In one embodiment, the membrane can be used as a filtration device to screen agents that disrupt or prevent molecular interactions. In one embodiment, the membrane allows for screening agents that disrupt or prevent molecular interactions using a small sample volume with efficient high-throughput screening applications.

Drug screening via nanopore silicon filters

A compound of the formula X-M-SEQ ID NO:1, or a derivative thereof, is provided, wherein X-M- represents an optional group comprising a protein transduction domain conjugated to the N-terminus of the amino acid sequence SEQ ID NO:1. Pharmaceutical compositions comprising and therapeutic methods using the compound are also provided.

Peptide and treatment for HIV-1 infection

This invention relates to cytidine deaminase inhibitors (Cytidine deaminase inhibitors) of cytidine deaminases and uses thereof.

Growing community of inventors

Rochester, NY, United States of America

Harold C Smith